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Summary ease), All male ALD patients and most carriers have an el­
evated level of VLCFA in plasma and fibroblasts, making
X-linked adrenoleukodystrophy (ALD) has been associ- ( h e  j .  ^  of ALD rdative,y straiglltforward (for over.
ated with mutations in a gene encoding an ATP-binding 
transporter, which is located in the peroxisomal mem­
brane. Deficiency of the gene leads to impaired peroxi­
somal p-oxidation. Systematic analysis of the open read­
ing frame of the ALD gene, using reverse transcriptase- 
PCR, followed by direct sequencing, revealed mutations 
in all 28 unrelated kindreds analyzed. No entire gene de­
letions or drastic promoter mutations were detected. In 
only one kindred did the mutation involve multiple exons. 
The other mutations were small alterations leading to mis- 
sense (13 of 28) or nonsense mutations, a single amino acid 
deletion, frameshifts, or splice acceptor-site defects. Mu­
tations affecting a single amino acid were concentrated in 
the region between the third and fourth putative trans­
membrane domains and in the ATP-binding domain. Mu­
tations were detected in all investigated ALD kindreds, 
suggesting that this gene is the only gene responsible for 
X-linked ALD, This overview of mutations is useful in the 
determination of structurally and functionally important 
regions and provides an efficient screening strategy for 
identification of mutations in the ALD gene.
view see Moser and Moser 1989).
Recently, a gene responsible for the disease in ALD pa­
tients was identified, using positional cloning, on the basis 
of its localization in Xq28 close to the color-vision genes. 
The ALD gene belongs to the superfamily of ATP-binding 
cassette (ABC)-transporter genes and encodes a protein, 
ALDP, containing six putative membrane-spanning re­
gions and one ATP-binding domain (Mosser et al. 1993). 
ALDP shows 30%  identity with PMP70, a peroxisomal 
membrane protein also belonging to the ABC-transporter 
family (Kamijo et al. 1990), Monoclonal antibodies raised 
against part of ALDP showed the protein to be located in 
the peroxisomal membrane. This suggests that this protein 
plays a role in the active transport of enzymes, cofactors, 
a n d /o r  substrates involved in the p-oxidation of VLCFA  
over the peroxisomal membrane (Contreras et al. 1994; 
Mosser et al. 1994). Intragenic deletions were initially 
found in ~ 6% of the unrelated ALD patients analyzed
Introduction
(Mosser et al. 1993). Also, two point mutations, one lead­
ing to a missense and the other to a nonsense mutation, 
have been described more recently (Cartier et al. 1993; 
Uchiyama et al. 1994). Moreover, ALDP could not be de­
tected in lymphoblast and fibroblast lines of several ALD 
patients (Contreras et al. 1994; Mosser et al. 1994).
, , , , i We report the first systematic analysis of ALD muta-
X-linked adrenoleukodystrophy (ALD) ,s a peroxisomal (io ovef fhe w hde protein. coding rcgion, in a largc
disorder characterized by uiipa.rcd peroX.somal P-ox.da- of tients. We identified ALD mutation8 in ali 28
tion of vcry-long-chain fatty acids (VLCFAs), which prob- independent kindreds studicd. This ovcrvicw of thc , c
ably is a consequence oi: reduced activation or the , , c i  ^ M , . . . . . . .  (I_ M , 1 . ,  i. r , and position or the mutations gives more insight into thc
VLCrAs. 1 his results m demyehnation or the nervous sys­
tem and adrenocortical insufficiency. The phenotype of 
ALD is highly variable, the most frequent phenotypes be­
ing childhood cerebral ALD, adrenomyeloneuropathy 
(AMN), and adrenocortical insufficiency (Addison dis-
structurally and functionally important regions of the pro­
tein and facilitates the design of a strategy for the identi­
fication of mutations in other ALD kindreds.
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Material and Methods
Oligonucleotide Primers
For nomenclature of the primers, the positions of the 5' 
end of the oligonucleotides are indicated, followed by 
“ F ,” for forward, or “R ,” for reverse primers. Positions 
refer to those given by Mosser et al. (1993) (EMBL data­
base Z 21876). Primers followed by an asterisk are located
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Flgur© I Schematic representation o f  primer positions. The box represents the open reading frame of the ALD mRNA, The lines before and 
behind the box represent the 5' UTR and 3' UTR, respectively. Lines 7-9  represent in irons in which primers were chosen to confirm the imitations on 
genomic DNA {not to  scale); lines I-V represent the overlapping PCR products that cover the entire open reading frame of the cDNA, Blackened 
triangles represent primers used in the amplification of the cDNA and sequencing (see also table 1); and unblackencd triangles indicate primers used 
for sequencing o f  these PCR products. Primers depicted in the intron sequences and below the cDNA arc used only in the confirmation of the 
mutations on genomic DMA. Triangles pointing to the right indicate forward primers, and those pointing to the left indicate reverse primers. The 
approximate position of the primers is indicated by the scale bar, denoting the nucleotide number of the cDNA (sec Mosscr ct al. 1993). Primer 
sequences are as follows: 303 F, AGCAACAATCCTTCCAGCC; 576F, AAAGCTGGCATGAACCGGG; 685F, CCTTGGTGAGCCGC ACCTTQ 
702F, TTCCTGTCG GTGTAT GTG GC; 914F, CCAGCAGACGTACT ACCGGG; 1300F, TG CT AC AG CGCTCCT ACC AG; 1479 F, GTGAAGAAG - 
GCAGCCTTGGA; 1681F, GTCACTTCAAGAGGCCCAGG; 1781F, CCAGGTGGTGGATGTGGAA; 1870F, TCAGGGTGGAGGAAGGCAT; 
1880F, GG A AG GCAT GCAT CTGCTC; 1890F, CATCTGCTCATCACAGGCCC; 2061F, T  ACCCG G A CTC A GTG G A G G A; 2312F, GATCTTCCA- 
G G C G G C C AAG G ;  2527F, AGGAGCTCTGCCAGATCCTG; 593R, CCGGTTCATGCCAGCTTTGGC; 821R, GGTAGCAGGGAGGGCGATGA; 
840R, GGATGGCACTGTTGACGAAGG; 931R, CGGTAGTAGGTCTGCTGGGA; 1145R, GAGGAACACCACGAGGCCGGj 1231R, TGTAGC- 
GCAGCTCCCCCTTC; 1384R, A ACT GCT CC AGC AT A AC AT ACC AO, 1409R, GGCGCTCCACACATACTTCA; 1542R, TGAAGGCTTCTG- 
TGCGCTC; 1752R, GGACACCAGACCGGCCTAT; 1861R, CTGGCCACCACCACCTCTi 1975R, ACACCACCGTACGTGGGC; 2016R, GCG- 
GGATGTAGAACATGC; 2114R, CAGGTCCTGCTCCGAGTAGC; 2194R, TCCTTCCAGTCACACATAGCCTC; 2204R, CGACAGGACGTC- 
CTTCCAGT; 2366R, CCGGTGGGTGATGGAGAG; 2478R, GCTGCTTCTCCTCCGTCAG; 2669R, TGTGATCCGAGCTTGGGG; 2686R, 
TGCTGCTGTCTCCTTCATGTG; 2742R, GGGTTTTCTAGGAGGAGGGG; 544F*, CAGGGGCCCTGTCGTCACAG (intron 7); 849F*# TGG- 
AGGGTGCACAGACTCTC (intron 8); 876R*, GCCGAGAGGAGAGTCTGTGC (intron 8); and 1078R*, AGGCCACCTCCTCCCCTCAG 
(intron 9).
in introns, and the numbers refer to their position in a par- pH 8,4, 2.25 mM MgCl2, 50 mM NaCI, 0.01% gelatin,
tial genomic DNA sequence encompassing part of intron 0.1% Triton X-100, 10% dimethylsulfoxide (DM.SO), 0,2
7 through exon 10 (Sarde et al. 1994), F o ra  schematic |Ug BSA/pJ (Boehringer-Mannheim), 0.65 mM dNTP, 1 ng
presentation of the primer positions and sequences, see each forward and reverse primer/jll, and 0.05 U AmpliTaq
figure 1 . DNA polymerase/|il (Perkin-Elmer). For fragments 2 and
5, 67 mM Tris-HCl pH 8,8, 6.7 mM MgCI2, 16.6 mM
Cell Lines, RNA Isolation, Reverse-Transcriptase-PCR, and ¡n h ^ S O *  lOmM B-mcrcaptocthanol, 10% DM SO, 0.2
Sequencing (ig BSA/fil, 0.65 mM dNTP, 1 ng each forward and re-
Fibroblast lines from 25 male patients and 3 female car- versc primer/pi, and 0.05 I) AmpliTaq DNA polymerase/
riers, who were diagnosed on the basis of clinical findings |i| were used. PCR was performed for 30 cycles (1 min at
and elevated levels of VLCFAs in plasma or fibroblasts 93°C, 1.5 min at 55°C, and 2 min at 72°C for fragment 1;
from 28 unrelated ALD kindreds, were cultured in Dul- and 1 min at 94°C, 1.5 min at 59°C, and 2 min at 72°C
becco’s modified Eagle medium, supplemented with 10% for fragments 2 and 5). PCRs of fragments 3 and 4 were
FCS and 50 \x$ gentamycin/ml or 50 U penicillin/ml and performed as described by Kemp et al. (19946), To remove
50 U streptomycin/ml. On trypsinization, the cells were free primers and nucleotides, products of fragments 1, 2,
washed twice in ice-cold PBS, RNA was isolated using gu~ and 5 were separated on agarose gels, extracted from the
anidinium isothiocyanate, as described elsewhere (Kemp et gel, and precipitated. For fragments 3 and 4, the QtA-
al. 1994b) or RNAzol (Biotecx), according to the protocol quick-spin PCR purification kit (Qiagcn) was used.
supplied by the manufacturer. Reverse transcription was Sequencing of fragments 1 , 2, and 5 was performed with
performed with random primers, using Maloney murine the T a q  DyeDeoxy terminator cycle sequencing kit (Ap-
leukemia virus-reverse transcriptase (Gibco-BRL). The plied Biosystems and Perkin-Elmer), using the primers in-
cDNA was amplified as five overlapping fragments (see fig* dicated in figure 1 and table 1, according to the protocol
1 and table 1). When two subsequent PCR reactions were supplied by the manufacturer. The sequence reactions
used, 5 jil of the first reaction was transferred to the sec- were run and analyzed, using an automatic sequencer (AIM 
oncl reaction, making an end volume of 100 ¡i\. PCR reac- 373A). Sequencing and analysis of fragments 3 and 4 were
tions of fragment 1 were performed in 10 mM Tris-HCl performed as described by Kemp et al. (1994/?),
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Table I
Primers Used for PCR and Sequencing of ALD cDNA
cDNA Fragment"
First-Step
I}CR
Second-Slop 
PCR Forward Sequencing Reverse Sequencing
1 ............................... 3 0 3 F -8 4 0 R 3 0 3 F -8 2 1 R 3 03 F, 576F 593R; 840R
11 ............................. 685F -1409R 7 0 2 F -1 3 8 4 R 702F, 914F 931R; 1145 R; 1384R
Ill ............................ 1300F-2016R N ot done 130 OF; 1479F; 1681F; 178 IF ; 
1880F
1542R; 1752R; 1861R; 1975R
I V ............................ 1870F-2366R N ot done 1880F; 2 0 6 1 F 2194R; 2204R
V ............................. 1870F-2686R 189Ö F-2669R 2 0 6 IF ; 2312F ; 2527F 2478R; 2669R
N o t e .— N umbers followed by " R ” or “ F” indicate primers used in the PCR. 
a Five overlapping fragments in which the open reading frame of the cDNA was amplified.
Confirmation of Mutations on Genomic DNA mutation resulting in a truncated protein product was dc-
Chromosomal DNA was isolated from EDTA-anticoag- tected and confirmed on genomic DNA (see below) was 
ulated blood or fibroblasts as described by Kemp et al. sequencing of the entire open reading frame not com- 
(19946) or using the salt-extraction method (Miller et al. pleted.
1988). Amplification of 100 ng of genomic DNA was per- Fragments representing ALD mRNA were obtained in
formed in 100 jxl, using oligonucleotide primers on both fibroblast lines. Since the PCRs were not necessarily
sides of the mutation (see table 2 ). Amplification with performed in the linear range of amplification, and since
primers 303F and 821R  was performed, as described above diis method of detection is able to reflect even very low
for fragment 1 of the cDNA, for primers 1479F and amounts of ALD mRNA, the level of transcription of the
1861R, and 1781F and 1861R conditions were used as de- ALD gene cannot be judged. Therefore, this method en-
scribed by Kemp et al. (1994b). The remaining PCRs were abled us merely to detect qualitative alterations or corn-
performed as described for fragment 2 and 4 of the cDNA. plete absence of the mRNA.
Mutations previously detected on cDNA were confirmed 
by H p a ll  digestion ( T 1 CM5 C  and C929A), by analysis of 
the length of a radioactively labeled PCR product on a
polyacrylamide gel (del 1801-1802) (Kemp et al. 19946) or
by direct sequencing of the PCR product as described different mutations is given in table 2 and figure 2 . Muta-
fc ^  fr — *  — A A / I  « 4 J M
In all kindreds, a mutation of the ALD gene was de­
tected. The nucleotide alteration was different for 24 of 
28 patients analyzed. N o indication of more than one mu­
tation was obtained in each case. An overview of all
above for the cDNA. tions are ordered 5' to 3', in five different classes: missense
To increase the specificity for genomic ALD sequences mutations (13), amino acid deletion (1), nonsense muta-
in Xq28, the amplification was performed in two subse- tions (4), and frameshift mutations caused either by dele-
quent steps for some of the PCRs (table 2 , note g). For tion of one or more nucleotides (8) or by splice site rnuta-
the first step, 0.1 ng DNA/|_U was amplified in 10 cycles. tions (2).
Subsequently, 5 jul product was transferred to the second Apart from these mutations, a G /A  polymorphism at
reaction, with a final volume of 100 jxl. For all sequence position 1934 (no amino acid change) and a C /G  polymor- 
reactions spanning exons 8 -1 0 , the annealing temperature phism at position 2 6 3 2  (downstream of the stop codon) 
in the cycle sequencing reaction was increased to 60°C, were observed (Kemp et al, 19946). In all cDNAs se- 
which is identical to the elongation temperature of the re- quenced, the C at position 754 was replaced by a T, alter­
ation* These conditions were used to exploit sequence ing an alanine to a valine residue, 
differences between the ALD gene and homologous se-
quences that are not located on Xq28. Analysis of Mutations on Genomic DNA
All mutations were confirmed in PCR products derived 
from genoinic DNA of the patient or an affected family 
member, using the information about the exon-intron or­
ganization of the ALD gene (Sarde et al. 1994). Mutations
Results
Detection of Mutations Affecting the ALD mRNA
Mutations in the ALD gene were analyzed in one C929A  and T 1045C  were verified by digestion of a geno-
affected person from each of 28 kindreds, by sequencing mic PCR product by H pall, The mutation C929A destroys
the ALD cDNA derived from male patients or female car- a H p a ll  recognition site. Complete digestion was moni-
riers. Overlapping PCR fragments representing the entire tored by using a PCR product containing an additional
open reading frame were sequenced directly on both H p a ll  site (primers 702F and 1145R). The mutation
strands (for primers see fig. 1 and table 1). Only when a T 1045C  created a novel H pall  site, which was confirmed
Ligtetibcrg et al.: Mutations in the ALD Gene
Table  2
Mutations in the Putative ALD Gene in Patients Studied
47
Type of Mutation and 
cDNA Alteration“
Amino Acid 
Alteration1 Exonc
Gcnomic-PCR
Primers
Genomic-
Mutation
Detection1 Phenotype0
Kindred 
Reference 
Nu inber
Missense:
C 696T f .......................... R 104C  (R) 1 3 0 3 F 4- 8 2 1 R 3 0 3 F , 8 2 1 R AMN 17
G 8 3 2 A ............................ S149N (N) 1 702F  +  1145 R 702F, 9 3 1R AMN 8
R 152P(K ) 1 702F +  1145R 702F, 931R ChALD 27
G874Ar'B ........................ R 163H  (R) 1 702F 4' 9 3 1 R 7 0 2 F , 9 3 1 R SympCar 14
G 9 6 6 C ............................ D194H (D) 1 685F +  114511 914F, 1145R Ch AU ) 12
T 1 0 4 5 C ......................... L220P (L) 1 9 1 4 F - I - 1 145R HpaW AMN 7
G U 8 2 A r ........................ C!2 6 6 K (G) 1 702F +  1231R 914F, 1 2 3 1 R AMN 24
G 1552A f .......................... R389H  (R) 3 1 4 7 9 F -I-1 8 6 1 R 1479 F, 1752R AMN 20
(2X):
G 2 2 1 1 A '........................ E609K (E) 8 5 4 4 F* 4 -1 0 7 8 R *h 5 4 4 P ,  876 R* AM N 13, 18
A 2 2 1 2 G ......................... E609G  (E) 8 544F * -I- 1 0 7 8 R *1’ 544F*, 876R * Ch A U ) 5
C 2 2 3 5 T r ........................ R 617C  (R) 8 5 4 4 P  -I- 2742R 544F*, 876R* ChALD 23
C 2 3 6 4 T r ........................ R 660W  (R) 9 5441’* -1- 2 7 4 2 R 2312  F, 1078R* AMN 21
Amino acid deletion:
del 2 3 5 5 - 2 3 5 7 ............. del 1657 ( V) 9 849F* +  2 4 7 8 R 1’ 2312 F, 1078R* ChALD 6
Nonsense:
C 783T f ........................... Q 1 3 3 h 1 7 0 2 F 4  9 3 1 R 702F, 931R ChALD 26
G 7 9 7 A ............................ W 1 3 7 1’ 1 68 5 F +  1145 R 702F, 9 3 1R ChALD 10
C 8 5 5 T ............................ Q 1 5 7 1' 1 702F  +  1145R 702F, 9 3 1R AMN 9
C 9 2 9 A ............................ Y 1 8 1 1' 1 702F  + 1145R HpaW ChALD 15
Frameshift:
del C442 ........................ A 1 9 > i 3 03 F +  821R 303F, 5 9 3 R ChALD 2
del C663 ........................ G 9 2 > 1 303 F +  8 4 0 R 576F, 8 2 1 R ChALD 22
del 1 1 7 1 - 1 1 7 8 ............. F 2 6 1 > 1 702  F +  123 IR 9141% 1231R ChALD 28
(4X):
d e l l  8 0 1 -1 8 0 2  ............. E 4 7 1 > 5 1 7 8 1 F 4 - 1 8 6 IR Polyacrylamide gel ChALD, AMN 3, 4, 16 ,25
alt 1989-2377  ............. P 5 3 4 > 6 -9 1 8 9 0 F 4 2 6 6 9 R 1890F, 1078R* AMN 11
Splice defect:
del 2 0 2 1 - 2 0 5 4 ............. R 5 4 5 > SA 7 1880F +  2132R 18801% 2114 R ChALD 1
ins 8 bp 2251f .............. R 6 2 2 > SA 9 849 F’* 4  1078R*1' 849 F*, 1078R* AMN 19
n Nucleotide numbers refer to Mosser ct al. (1993), E M B L  database Z 21876 ,
l> Amino acid numbers refer to Mosser e ta l ,  (1993) (start codon is 4-1); in case of a frameshift or splice-defect mutation, the last amino acid residue 
that is not altered in the expected protein product is indicated. The corresponding residue in the human PMP70 protein is indicated in parenthesis. 
c Exon number affected by the mutation. SA =  alteration of the splice acceptor site (for details see Kemp e( al, 1994a).
d Numbers indicate primers used for sequencing, HpaW ~  mutation confirmed by H po II digestion; and polyacrylamide gel =  deletion monitored as 
a decrease in size of the PCR product.
c Phenotype of the patient tested in this family— ChALD -  childhood Aid); and SympCar asymptomatic carrier. 
f Mutation that might be the result o f  deamination of methylated CpG.
B Mutation detected in a female carrier and for which no other family material was available.
h PCR input material was derived from PCR with primer 544F  and primer 2669R  (10 cycles). (See Material and Methods.)
using a comparable PCR product (primers 914P and mothers (carriers on the basis of elevated levels of VLCFA) 
1 145R). The dinucleotide deletion at positions 1801 and and unaffected sisters, that these alterations were indeed
1802 was monitored by analysis of radioactively labeled 
PCR products overlapping the deletion site on a polyacryl-
present in the affected alleles, except for the G874A alter­
ation. No other material was available from the kindred in
amide gel. The remaining mutations were confirmed by di- which the latter mutation was detected, and thus definitive
rect sequencing of a genomic PCR product, using primer 
combinations as indicated in table 2 .
For the kindreds carrying the missense mutations 
G874A and C 2235T , and for one of the kindreds with a
proof that this alteration is indeed present in the mutated 
chromosome is not available. All other mutations were de­
tected in male patient material.
Mutations located in exon 8 , intron 8 , and exon 9 were
dinucleotide deletion at positions 1 8 0 1 -1 8 0 2 , the cl)N A  difficult to detect in PCR products derived from genomic 
fragments were derived from fibroblasts of female carriers. DNA, as a result of highly homologous sequences with 
It was established, by analysis of genomic DNA from exactly the same length amplified from unknown regions
48 Am.J. Hum. Genet. 56:44-50, 1995
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F i g u r e  2  Distribution o f  mutations in the ALD gene. The boxes
represent coding regions distributed over the 10 exons (Sardc et al. 1994);
the lines between these boxes represent introns (not in scalc), and those
before exon 1 and behind exon 10 represent UTRs of the transcribed
sequence. Hatched boxes represent regions encoding the six putative
membrane-spanning domains (Klein et al. 1985); and the cross-hatched
boxes represent the region encompassing the ATP-binding folds and their
>1
interjacent region. Each vertical bar represents the location of a mutation 
detected in this study. For the framcshift mutations» the last amino acid 
that is not altered by the mutation is indicated, The arrows represent the 
alteration of the splice acceptor site used, an alteration due either to 
mutation of the authentic splice acceptor site, resulting in the use of a 
cryptic acceptor site farther downstream, or to the generation of a novel 
splice acceptor site upstream of the actual splice site.
outside Xq28 (see also Sarde et al« 1994). With a primer in 
intron 7 and in the UTR, DNA from a human control and 
from a somatic cell hybrid containing Xq28 as the only 
source of human DNA was amplified. Comparison of se­
quences derived from either PCR product revealed differ­
ences between the ALD gene and the homologous se­
quences outside Xq28, which were used to design primers 
with preference for the ALD gene, These primers were ap­
plied under stringent conditions to generate PCR products 
and sequences that were more Xq28 specific. Although 
amplification of other copies was not completely avoided, 
it was possible to confirm the mutations previously ob­
served in the cDNA, by comparison of sequences derived 
from control and patient DNAs.
The most drastic alteration of the gene structure found 
led to a frameshift at amino acid position P534* In the 
cDNA, the region between nucleotide 1988 in exon 6 and 
nucleotide 2378, the start of exon 10) was absent, while 88 
nucleotides of unknown origin were inserted. Analysis of 
the mutation at the genomic level revealed a replacement of
complex) deletion was observed, in agreement with the 
low (6%) frequency of such mutations reported by Mosser 
et al. (1993). No deletion of the entire gene has been re­
ported to date.
The ALD gene product shows all characteristics of an 
ABC transporter, with only a single domain containing pu­
tative membrane-spanning segments and one ATP-binding 
domain. The functional entity of a typical ABC transporter 
consists of two sets of these domains. In some transport­
ers, both sets are assembled in a single polypeptide chain 
(like P-glycoprotein), while others are formed by dimeriza- 
tion of two polypeptides with a structure analogous to 
that of ALDP (like the peptide transporter, which is en­
coded by two closely linked genes on chromosome 6) (for 
review see Higgins 1992). This suggests that ALDP func­
tions as a homodimer or forms a heterodimer with a ho­
mologous protein. Mutations affecting this putative part­
ner would most likely also lead to an ALD phenotype. We 
can now practically exclude the presence of such a puta­
tive gene on the X  chromosome, as we found mutations in 
the known ALD gene in all kindreds tested. Formally, we 
cannot exclude the possibility that mutatiorts in an autoso­
mal gene encoding a presumed partner of ALDP are re­
sponsible for the disease in some rare patients. It has been 
proposed that PMP70 might be such a partner (Valle and 
Gärtner 1993).
In 14 (50%) of 28 kindreds, the mutation affected a sin­
gle amino acid residue. Since no direct functional assay is 
available, definitive proof is lacking that these mutations 
cause ALD. However, it is unlikely that these alterations 
are merely polymorphisms, since in all these cases only one 
alteration was found, which was different for 13 of 14 kin­
dreds. None of these alterations were detected in kindreds 
with a mutation resulting in a truncated product. More­
over, although ALDP and PMP70 share only 30% amino 
acid identity, 10 of 13 different mutations affect amino 
acids conserved between both proteins, and 2 mutations 
affect residues with very conservative changes between 
ALDP and PM P70 (see table 2 ), suggesting that they in­
deed affect functionally or structurally important residues 
of the protein. In the remaining mutation, S149N, the 
ALDP residue is replaced by the corresponding PMP70 
residue. By analogy with mutations detected in the cystic
V J  * V* V I  * V M  1^4 V *  a  1 ( h  L  L I  I V - L ^ V * 1  I  W / I  1 A 1 w* I V  T  v A J* S #  T A V* V * L I k  L /  I  V i  W  1 J  I  V I  & V X |  ♦ |  f  4
i 100o> ✓* i i *.• i hbrosis transmembrane conductance-regulator gene, an-a region between nucleotide 1988 tn exon 6 and nucleotide . . f f c .. • i i
2368 in exon 9, by a segment of ^ 5 7 4  nucleotides, which 
apparently harbors a cryptic splice donor site 89 nucleotides
other member of the family of ABC transporters involved 
in a genetic disease, one might expect to find a high fre~
downstream of nucleotide 1988. Sequence comparison re- .^U^ nc^ a t^eratj ^ ®  ^  ATI binding domain, espe 
vealed that this segment is derived from an internal part of ^ ally ‘n ** ATP-bmding-site motifs (for review see
intron 7, which is ~ 2  kb long (Sarde et al. 1994).
D i s c u s s i o n
Tsui 1992). However, only three different mutations, 
affecting two different amino acid residues, were found in 
one of the ATP-binding-site motifs. These three muta­
tions affect amino acid residues that are strongly conserved 
We have detected a mutation in the coding region of the among different ABC transporters (Mosser et al, 1993). Al- 
ALD gene in all 28 investigated ALD kindreds. N o indica- though the missense mutation R660W  and the deletion of 
tions of drastic promoter mutations were obtained, as an isoleucine at position 657  are located 30 and 27 amino 
RNA could be detected in all patients. A single partial (and acids downstream of the second ATP-binding site motif,
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respectively, they are situated within a strongly conserved 
region. Possibly, these latter two mutations affect the 
structure of the ATP-binding domain, leading to dimin­
ished ATP binding or hydrolysis, Recently, a search for 
mutations in exons 6 and 8 that encode the 2 ATP-bind- 
ing-site motifs in 50 French patients uncovered four mis- 
sense mutations (including the R 617C  mutation also 
found by us [Fanen et al. 1994]). In our series, the majority 
of missense mutations were found far upstream from the 
ATP-binding domain. Remarkably, the relative number of 
missense mutations is high in exon 1, especially between 
the third and fourth putative transmembranc regions, 
which can only be partially attributed to the high CpG 
richness in this region (see table 2 ). Apparently, these mu­
tations affect ALDP function, suggesting that this is a func­
tionally or structurally important region that might be in­
volved in substrate selection or transport or in homo- or 
heterodimerization.
Mutations leading to a truncated and possibly labile 
protein are detected in 50%  of the kindreds. These trun­
cations are caused by nonsense mutations, deletions of 
one or a couple of nucleotides, a deletion affecting 
multiple exons, or splice acceptor-site mutations. In all 
these cases, the predicted translation products are trun­
cated upstream or within the ATP-binding domain, sug­
gesting that the mutations result in complete absence of 
ALDP function.
The majority of mutations were found only once in the 
kindreds investigated. Exceptions arc one of the ATP- 
binding-site motif mutations (E609K), which was de­
tected in 2  kindreds, and a dinucleotide deletion resulting 
in a frameshift immediately downstream of E 471 , which 
was observed in 4  of the above kindreds and 1 of 10 
different kindreds screened for this mutation on genomic 
DNA only (Kemp et al. 1994£>). The five kindreds with the 
dinucleotide deletion had different haplotypes in the ALD 
region, suggesting that this mutation occurred indepen­
dently in these kindreds. In the two kindreds with the mu­
tation G 2211 A, the haplotype of the polymorphic markers 
close to the ALD gene was different (results not shown), 
making it likely that these mutations also result from two 
independent events.
The observed distribution of the mutations may be used 
to develop a strategy to detect mutations in other ALD 
kindreds. Screening for the mutation is the most reliable
genetic assay to establish the carrier status of females in References 
ALD kindreds. This is especially important, since in 5 % -  
10% of female carriers no elevated level of VLCFA is de­
tected (for review see Moser and Moser 1989). Starting 
with the screening of exon 5 for the presence of the recur­
rent dinucleotide deletion at positions 1801 -’ 1802, fol­
lowed by analysis of the large coding region of exon 1, in 
which mutations were found frequently (see table 2 and 
fig. 2 ), a majority of mutations are expected to be discov­
ered ('18 of 28 mutations in our series). The dinucleotide 
deletion is easily testable on genomic DNA, by using prim­
ers flanking the putative hot spot and by scoring for the 
size difference (Kemp et al. 19946), Mutations in the first 
exon can easily be detected by analysis of genomic PCR 
products, e.g., by SSCP or direct sequencing. When no mu­
tations are found, the remaining exons should be tested 
with emphasis on exons 8 and 9, These exons are difficult 
to examine at genomic level, because of the presence of 
very homologous sequences elsewhere in the genome (also 
see Sarde et al. 1994), and should preferentially be investi­
gated on PCR products derived from cDNA. Therefore, 
collecting fibroblasts of patients is advisable when the mu­
tation has not been previously defined in the kindred,
Considerable phenotypic variation can be found within 
a single X-tinked ALD kindred. This indicates that, apart 
from the mutation in the ALD gene, other gcnetie or envi­
ronmental factors may modulate the phenotype (Maestri 
and Beaty 1992). However, a correlation between geno­
type and phenotype might still exist: a certain type of ALD 
mutation might, for instance, be present in kindreds with 
A M N  patients only. The identification of ALD mutations 
will allow further investigation of the relationship between 
genotype and phenotype.
In conclusion, the systematic analysis of X-linked ALD 
mutations demonstrates that the identified ALD gene is 
most likely the only gene responsible for ALD on the X  
chromosome, limiting mutation detection to the analysis 
of only a single gene. Moreover, the distribution of the 
mutations in this gene suggests an efficient screening strat­
egy, which is of special relevance for the identification of 
carriers in ALD kindreds.
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